JMI Laboratories, North Liberty, Iowa, USA.
Antimicrob Agents Chemother. 2012 Mar;56(3):1639-42. doi: 10.1128/AAC.06067-11. Epub 2011 Dec 19.
Oritavancin exhibited potent activity against vancomycin-susceptible (MIC(50) and MIC(90), 0.015/0.03 μg/ml) and vanB-carrying E. faecalis isolates (MIC(50) and MIC(90), 0.015 and 0.015 μg/ml). Higher (16- to 32-fold) MIC(50)s and MIC(90)s for vanA-harboring E. faecalis were noted (MIC(50) and MIC(90), 0.25 and 0.5 μg/ml), although oritavancin inhibited all strains at ≤ 0.5 μg/ml. Vancomycin-susceptible and vanB-carrying E. faecium strains (MIC(50) and MIC(90), ≤ 0.008 and ≤ 0.008 μg/ml for both) were very susceptible to oritavancin, as were VanA-producing isolates (MIC(50) and MIC(90), 0.03 and 0.06 μg/ml). Oritavancin exhibited good in vitro potency against this collection of organisms, including vancomycin-resistant enterococci.
奥他万古霉素对 vancomycin-susceptible（MIC(50) 和 MIC(90)，0.015/0.03μg/ml）和携带 vanB 的粪肠球菌分离株表现出强大的活性（MIC(50) 和 MIC(90)，0.015 和 0.015μg/ml）。vanA 携带的粪肠球菌的 MIC(50) 和 MIC(90) 更高（16 到 32 倍）（MIC(50) 和 MIC(90)，0.25 和 0.5μg/ml），尽管奥他万古霉素在 ≤ 0.5μg/ml 时就能抑制所有菌株。vancomycin-susceptible 和携带 vanB 的屎肠球菌菌株（MIC(50) 和 MIC(90)，均≤0.008 和≤0.008μg/ml）对奥他万古霉素非常敏感，产生 VanA 的分离株也是如此（MIC(50) 和 MIC(90)，0.03 和 0.06μg/ml）。奥他万古霉素对包括耐万古霉素肠球菌在内的这一系列生物体具有良好的体外效力。
